$0.06

Are you using our Portfolio Manager?

Manage your stocks with our free tool.

Get Started

General Information

Actinogen Medical Limited
ACW
http://www.actinogen.com.au
Biotechnology
37
620

Current Price Data+

Current Price $0.060
Open $0.060
High $0.060
Low $0.060
Last Close $0.060
Volume 62950
Price Movement - ( No change )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

Company Overview

Business Description

Actinogen Medical Limited (ACW, formerly Actinogen Limited) is focused on the treatment of Alzheimer's Disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious conditions of Alzheimer's and dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. Xanamem is a lead product of Actinogen for the treatment of Alzheimer.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 A -3.6 -0.6 0.0% 0.0 0.0 0.0% 0.0%
2015 A -5.4 -1.3 0.0% 0.0 0.0 0.0% 0.0%
2014 A -0.4 -0.3 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Actinogen Medical (ACW) $38M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL (CSL) $57,431M -0.1719 0.2302 0.3448 40.8881 33.2363 24.7140 1.34% 1.39% 1.91%
Mesoblast (MSB) $842M 0.0000 0.0000 0.0000 8.9940 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $386M 0.1852 0.1031 0.0742 13.4206 12.1662 11.3260 5.18% 5.76% 6.18%
Sirtex Medical (SRX) $943M 0.3228 -0.0348 0.1291 17.7223 18.3616 16.2619 1.84% 1.81% 1.92%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 3.00 0.00
Market 1.03 16.00 1.27 1.02
Sector 0.74 13.50 3.07 1.25

Directors

Name Position Start Date
Dr John (Bill) William Ketelbey Chief Executive Officer, Managing Director 18 Dec 2014
Dr Geoffrey E.D Brooke Non-Executive Chairman, Non-Executive Director 1 Mar 2017
Dr Anton Uvarov Non-Executive Director 16 Dec 2013
Dr Jason Loveridge Non-Executive Director, Interim Chairman 1 Dec 2014

Management

Name Position
Peter Webse Company Secretary
Vincent Ruffles Vice President of Clinical Research

Substantial Shareholders

Holding Name
48,147,864 (7.94%) Edinburgh Technology Fund Limited
36,250,000 (5.98%) Martin Rogers
34,717,184 (5.72%) Tisia Nominees P/L
34,717,184 (5.72%) J K Holdings Pty Ltd

Calendar of Events

Date Event
26 February 2018 Report (Interim)
23 October 2017 Report (Annual)
30 August 2017 Report (Annual)
30 August 2017 Report (Prelim)

© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.